SELLAS (SLS) Is Two Deaths From a Phase 3 Answer It Can't See Yet. Here's the Distribution.

SELLAS Life Sciences (NASDAQ: SLS) has done something almost no other name on the retail stream can claim this month: it has an actual, verifiable, binary event sitting two data points away — and the company itself does not yet know the answer.

The stock closed Friday at $13.19, up roughly 12% on the day, and was indicated higher again in Monday's pre-market. Over the past four weeks it has run from the mid-$8s toward $15, briefly tagging a 52-week high of $15.88 against a 52-week low of just $1.39. That is close to a ten-bagger range inside a single year, and the move has almost nothing to do with revenue — SELLAS has essentially none — and almost everything to do with a clock that is about to run out.

What is actually happening

SELLAS is a late-stage cancer immunotherapy company. Its lead asset, galinpepimut-S (GPS), is a peptide vaccine that trains the immune system against WT1, a protein over-expressed in acute myeloid leukemia (AML) and a long-standing target that the field has chased for two decades without a Phase 3 win.

GPS is being tested in the pivotal Phase 3 REGAL trial — a randomized, open-label, 127-patient study comparing GPS maintenance monotherapy against investigator's choice of best available therapy in AML patients who reached a second complete remission after second-line salvage therapy. This is a brutal patient population: relapsed AML in second remission has a grim survival curve and no approved maintenance standard. The primary endpoint is the one that matters most to regulators and clinicians alike: overall survival — the interval between randomization and death from any cause.

Here is the mechanic that makes REGAL a live catalyst rather than a someday-catalyst. The trial is event-driven: its final analysis is triggered not by a calendar date but by the accumulation of a pre-specified 80 deaths across both arms. On May 12, 2026, SELLAS disclosed that its contract research organization had informed it that 78 events had occurred as of May 11 — and that the company remains fully blinded to the outcome. Two events from the database lock. Two events from unblinding. Two events from topline results that either validate a twenty-year target or send a peptide vaccine to the same graveyard that has swallowed most of its predecessors.

That is why the stock is moving. The market is not pricing a business; it is pricing a coin that is already in the air.

Briefings like this land in members' inboxes before the market prices them in. Join free →

Why the timing itself has become the debate

There is a subtlety in REGAL's slow march to 80 events that the stream has turned into a Rorschach test. The trial's estimated primary completion date was December 2025. It is now mid-2026, and the 80th event still has not printed. Events are accruing more slowly than the original statistical model assumed.

Bulls read that one way: if patients are dying more slowly than projected, someone in the trial is living longer than expected — and in a two-arm survival study, the optimistic interpretation is that the GPS arm is the reason. Analysts at Alliance Global leaned on exactly this logic when they raised their price target to $25 and reiterated a buy, and the published sell-side consensus target sits near $27.50 — well above the current print.

Bears read the identical fact the other way: slow event accrual in an open-label survival trial is not proof of anything, the delay burns cash and patience, and open-label OS endpoints carry their own methodological baggage that a skeptical FDA review can seize on even if the topline number looks favorable. Both camps are staring at the same two-events-away line and seeing opposite futures.

So the real question — the one that decides whether Friday's $13 is a floor or a ceiling — is not whether the readout is coming. It is coming. The question is what the distribution of outcomes actually looks like once you strip out the hope, price in the balance sheet, and map where this stock realistically lands in each scenario.

That is what the rest of this briefing does.